Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00325234
First received: May 10, 2006
Last updated: April 26, 2011
Last verified: April 2011
Results First Received: April 26, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Breast Cancer
Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Gemcitabine
Drug: Vinorelbine

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Pemetrexed/Carboplatin Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1. Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC 5.0 mg*min/mL. The cycle of treatment was 21 days.
Gemcitabine/Vinorelbine

Vinorelbine 30 mg/m^2 was given over approximately 6-10 minutes on Day 1 and Day 8.

Gemcitabine 1200 mg/m^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.

Total Total of all reporting groups

Baseline Measures
    Pemetrexed/Carboplatin     Gemcitabine/Vinorelbine     Total  
Number of Participants  
[units: participants]
  69     66     135  
Age  
[units: years]
Mean ± Standard Deviation
  51.9  ± 11.38     52.3  ± 10.40     52.1  ± 10.87  
Gender  
[units: participants]
     
Female     69     66     135  
Male     0     0     0  
Race/Ethnicity, Customized  
[units: participants]
     
Caucasian     67     61     128  
African     1     3     4  
Hispanic     0     1     1  
East Asian     1     0     1  
West Asian     0     1     1  
Region of Enrollment  
[units: participants]
     
Spain     18     18     36  
Switzerland     5     4     9  
Israel     9     9     18  
Germany     9     12     21  
Italy     16     14     30  
Turkey     5     3     8  
South Africa     7     6     13  
Eastern Cooperative Oncology Group (ECOG) Performance Status [1]
[units: participants]
     
ECOG 0     39     39     78  
ECOG 1     28     27     55  
ECOG 2     2     0     2  
Hormonal Receptor Status [2]
[units: participants]
     
Estrogen and Progesterone Negative     19     21     40  
Estrogen and/or Progesterone Positive     49     44     93  
Unknown     1     1     2  
Human Epidermal Growth Factor Receptor 2 (HER-2/Neu) [3]
[units: participants]
     
Positive     12     13     25  
Negative     53     49     102  
Not Performed     0     1     1  
Unknown     4     3     7  
Tumor Differentiation Grade [4]
[units: participants]
     
Grade I     6     3     9  
Grade II     25     27     52  
Grade III     32     30     62  
Unknown     6     6     12  
Pathological Diagnosis [5]
[units: participants]
     
Carcinoma, Ductal, Breast     64     54     118  
Carcinoma, Lobular, Breast     4     5     9  
Carcinoma, Inflammatory, Breast     1     3     4  
Carcinoma, Mixed Cell, Breast     0     1     1  
Other     0     3     3  
[1]

The Eastern Cooperative Oncology Group (ECOG) scales and criteria are used by doctors to assess disease progression, assess the patient’s living ability, and determine prognosis. The scale is as follows:

0-Fully active, able to carry on all pre-disease performance without restriction. 1-Restricted in activity but ambulatory and able to perform sedentary work. 2-Ambulatory but unable to work. Up and about > 50% of waking hours. 3-Capable of only limited selfcare, confined to bed or chair > 50% of waking hours. 4-Completely disabled. Cannot self care. Totally confined to bed or chair. 5-Dead

[2] Hormone receptor status is a positive or negative measure of estrogen (ER) or progesterone (PR) hormone receptors found in cancer cells. In hormone receptor negative tumors, estrogen and/or progesterone are not present in cancer cells. In hormone receptor positive tumors, estrogen and/or progesterone hormone receptors are present in the cancer cells.
[3] The Human Epidermal Growth Factor Receptor 2 plays an important role in cell growth and development. HER-2/Neu status is determined by an assay. A positive HER-2/Neu result indicates that HER-2 gene receptors are present; negative HER-2/Neu indicates the absence of HER-2 gene receptors.
[4]

Classification of tumors into one of four grades based upon how similar in appearance the tumor cells are to normal cells, and by how many tumor cells are dividing. The more tumor cells that are dividing, the greater likelihood of tumor growth and the higher the tumor grade. A lower tumor grade is associated with a better prognosis.

Grade 1 - Well-Differentiated, Low cell division Grade 2 - Moderately Differentiated, Moderate cell division Grade 3 - Poorly Differentiated, High cell division Grade 4 - Undifferentiated, High cell division

[5] This measure is the specific diagnosis of breast cancer based upon pathological diagnosis.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Tumor Response Rate   [ Time Frame: Baseline up to 30 days of follow-up after 21 cycles of treatment ]

2.  Secondary:   Duration of Response (DOR)   [ Time Frame: Time of response to progressive disease (up to 19 months) ]

3.  Secondary:   Time to Progressive Disease (PD)   [ Time Frame: Baseline to measured PD (up to 25.1 months) ]

4.  Secondary:   Time To Treatment Failure (TTTF)   [ Time Frame: Baseline to end of treatment (up to 21.9 months) ]

5.  Secondary:   Time to Response   [ Time Frame: Baseline to response (up to 7.8 months) ]

6.  Secondary:   Number of Participants With Adverse Events (AE)   [ Time Frame: every cycle up to twenty-one 21-day cycles (plus 30 days of follow-up) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information